The guidance raise and strong beat on both EPS and revenue suggest accelerating momentum in the core non-COVID portfolio. Watch for continued execution on the cost realignment program and pipeline catalysts including berobenatide Phase 3 starts and Talzenna/Tukysa label expansions.
Drugs in focus
PFE drug pipeline →Abrysvo
● Neutral Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already approved and commercially available since mid-2023.
- Next catalyst
- None dated
What to watchAbrysvo has no upcoming PDUFA dates or pivotal readouts; it is an approved, commercial product. Watch Pfizer's quarterly earnings reports for Abrysvo sales trends, particularly during the fall RSV season (September-January). The key competitive dynamic to monitor is whether Abrysvo can gain market share from GSK's Arexvy following its broader adult label (18-59 at-risk) and whether the GBS warning materially impacts uptake.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 3 $30.00entry
- T+1 · 13d ago +2.63%α +0.98% · $30.79
- T+5 · 7d ago −2.13%α −1.55% · $29.36
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Pfizer reported Q3 2026 adjusted diluted EPS of $0.87, beating the $0.73 consensus by 19.2%, on revenue of $16.58B versus the $15.88B estimate. The company raised full-year 2026 revenue guidance by $1.5B at the midpoint to $62.0-$64.0B and raised/narrowed adjusted EPS guidance to $2.95-$3.05, reflecting strong year-to-date performance and confidence in the business.
Key Financial Metrics
Key Facts
- Q3 2026 adjusted diluted EPS of $0.87 beat consensus of $0.73 by 19.2%
- Q3 2026 revenue of $16.58B was above the $15.88B consensus estimate
- Full-year 2026 revenue guidance raised by $1.5B at the midpoint to $62.0-$64.0B
- Full-year 2026 adjusted diluted EPS guidance raised and narrowed to $2.95-$3.05 from $2.80-$3.00
- Non-COVID product revenue grew 7% operationally; launched and acquired products grew 32% operationally
- Eliquis revenue up 25% operationally, Padcev up 55%, Vyndaqel family up 12%, Lorbrena up 43%
- Paxlovid revenue declined 63% operationally, Comirnaty down 29%, Prevnar family down 10%
- Cecile Guegan appointed CFO and EVP effective November 1, 2026
- No share repurchases completed in 2026; $3.3B remaining authorization
Financial Impact
Q3 adjusted EPS of $0.87 vs consensus $0.73; revenue $16.58B vs consensus $15.88B; FY guidance raised by $1.5B at midpoint for revenue and $0.10 at midpoint for adjusted EPS
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Primary Care | $7.0B | -9.0% |
| Oncology | $4.3B | +10.0% |
| Specialty Care | $3.3B | +7.0% |
| Hospital and Biosimilars | $1.6B | +2.0% |
| Pfizer CentreOne | $300.0M | -13.0% |
Risk Factors
- COVID-19 product revenue continues to decline (Paxlovid -63%, Comirnaty -29%)
- Prevnar family revenue down 10% on lower vaccination rates and market share erosion
- RD spending increased 18% operationally, pressuring margins
- Restructuring charges of $791M in Q3 reflect ongoing cost realignment program
- Generic/biosimilar competition expected to impact revenue by approximately $1.1B in 2026
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000078003-26-000125 |
| Document: pfe-20261103.htm | 0000078003-26-000125 |
| Document: 0000078003-26-000125-index-headers.html | 0000078003-26-000125 |
| Document: 0000078003-26-000125-index.html | 0000078003-26-000125 |
| Document: 0000078003-26-000125.txt | 0000078003-26-000125 |
| 8-K Data (Synthetic) | 0000078003-26-000125 |
Track record
21 reports on PFE
5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +17.28% at T+60 after the Aug 4, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 3, 202613d ago 8-K Neutral 2/10 Entry $30.79 Now $28.89 −6.17% settles Feb 2
- Nov 3, 202613d ago 8-K Bullish 6/10 Viewing Entry $30.00 Now $28.89 −3.70% settles Feb 1
- Oct 30, 202618d ago Court Ruling Neutral 2/10 Entry $30.67 Now $28.89 −5.80% settles Jan 29
- Oct 23, 202624d ago Institutional Cluster Mixed 3/10 Entry $30.03 Now $28.89 −3.80% settles Jan 21
- Aug 13, 202613w ago Court Ruling Neutral 1/10 Entry $26.79 to $29.23 Now $28.89 +7.84% ▲ +9.11% +12.15% vs SPY
- Aug 12, 202613w ago Insider Buy Bullish 5/10 Entry $26.80 to $29.39 Now $28.89 +7.80% ▲ +9.66% +15.14% vs SPY
- Aug 12, 202613w ago Insider Cluster Bullish 6/10 Entry $26.80 to $29.39 Now $28.89 +7.80% ▲ +9.66% +15.14% vs SPY
- Aug 6, 202614w ago Insider Cluster Bullish 4/10 Entry $26.20 to $30.52 Now $28.89 +10.27% ▲ +16.49% +18.16% vs SPY
- Aug 5, 202614w ago Insider Buy Bullish 5/10 Entry $26.20 to $30.52 Now $28.89 +10.27% ▲ +16.49% +18.16% vs SPY
- Aug 5, 202614w ago Insider Cluster Neutral 3/10 Entry $26.20 to $30.52 Now $28.89 +10.27% ▲ +16.49% +18.16% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers